• Profile
Close

A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002)

Cancer Chemotherapy and Pharmacology Sep 19, 2017

Ikezawa Y, et al. - Experts planned to select the most suitable regimen as a third- or fourth-line therapy for wild-type EGFR non-small cell lung cancer (NSCLC). As compared to erlotinib, S-1 as a third- or fourth-line therapy for wild-type EGFR NSCLC exhibited numerically better clinical outcomes.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
  • Exclusive Write-ups & Webinars by KOLs

  • Nonloggedininfinity icon
    Daily Quiz by specialty
  • Nonloggedinlock icon
    Paid Market Research Surveys
  • Case discussions, News & Journals' summaries
Sign-up / Log In
x
M3 app logo
Choose easy access to M3 India from your mobile!


M3 instruc arrow
Add M3 India to your Home screen
Tap  Chrome menu  and select "Add to Home screen" to pin the M3 India App to your Home screen
Okay